| Course | NR 668 Psychiatric-Mental Health Capstone Practicum & Intensive |
|---|---|
| Week | 4 |
| Paper type | Case defense write-up |
| Length | About 1,100 words, 5 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN, Psychiatric-Mental Health Nurse Practitioner (PMHNP) |
| Updated | October 2026 |
Free sample paper for NR 668 Week 4
Case Defense Write-Up: Starting Quetiapine Rather Than Lamotrigine for Bipolar II Depression in a Patient at Metabolic Risk, With the Objection at Full Strength
Student Name
College of Nursing, Chamberlain University
NR 668: Psychiatric-Mental Health Capstone Practicum & Intensive
Instructor Name
Month Day, Year
Case Defense Write-Up: Starting Quetiapine Rather Than Lamotrigine for Bipolar II Depression in a Patient at Metabolic Risk, With the Objection at Full Strength
The Plan Being Defended
For the patient from the case conference, whose bipolar II depression carried mixed features and passive thoughts of death, I started quetiapine, titrated to 300 mg at bedtime over four days, and tapered escitalopram over one week. Lamotrigine was considered and not chosen as the first step.
The Objection, at Full Strength
A skeptical colleague would put it like this: "Your patient has a body mass index of 31, an A1C of 5.8%, raised lipids and a parent with diabetes. Quetiapine causes weight gain and worsens glucose and lipids, and those effects build over months. Lamotrigine has no metabolic burden, is well tolerated and is particularly good at preventing the depressive episodes that dominate bipolar II disorder. Bipolar II is a lifelong illness. You've chosen a drug whose harms accumulate in exactly the patient most likely to suffer them, to save a few weeks. And at 300 mg the sedation may cost them their job."
What the Objection Gets Right
The metabolic risk is real and this patient is near the threshold for diabetes. Lamotrigine is better suited to long-term prevention of bipolar depression and lacks quetiapine's weight and glucose effects. Sedation at 300 mg could affect work, and the patient is a graphic designer who works on deadlines. If the choice were only about the next two years, lamotrigine would likely be the better drug.
Where the Position Still Holds
The choice was about the next four weeks first. Lamotrigine must be titrated slowly to reduce the risk of serious rash, typically reaching a usual maintenance dose only after about six weeks, and its effect on acute bipolar depression is less established than its preventive effect. Quetiapine is listed as a first-line treatment for acute bipolar II depression in the current guideline (Yatham et al., 2018), and it helps sleep, which had fallen to four hours in a mixed state. The patient had passive thoughts of death, a family history of suicide and regular alcohol use. Mixed features with insomnia are a period of raised risk, and leaving the patient largely untreated for six weeks, after stopping the antidepressant, would trade a metabolic risk that builds over months for a mood and safety risk that is present now.
The objection also assumes the choice is permanent. It does not need to be.
Evidence Used to Settle Points
That antidepressants should be stopped rather than continued: adjunctive antidepressants did not improve outcomes in bipolar depression in a large trial (Sachs et al., 2007), and the international task force advises against antidepressant monotherapy and against antidepressants in mixed states (Pacchiarotti et al., 2013).
That quetiapine is a reasonable first step: guideline first-line status for bipolar II depression (Yatham et al., 2018).
That metabolic monitoring matters: the same guideline recommends baseline and follow-up weight, glucose and lipid monitoring with second-generation antipsychotics.
The Plan After the Challenge
The objection changed three things. First, quetiapine is framed to the patient as the acute treatment, with a planned review at 12 weeks of whether to continue it or move to lamotrigine for maintenance once mood is stable. Second, metabolic monitoring was brought forward: weight at every visit, fasting glucose and lipids at 6 weeks rather than 12, and a referral to the clinic's nutrition service at the start. Third, the dose will be held at the lowest effective level; if the patient responds at 150 or 200 mg, the titration stops there, given work sedation.
What the Guideline Does and Does Not Settle
The guideline ranks treatments by evidence for acute bipolar II depression and places quetiapine first (Yatham et al., 2018). It does not rank by metabolic risk in an individual patient, and it does not tell a clinician how to weigh six weeks of depression against months of weight gain. Those weights belong to the clinician and the patient. A guideline that tried to settle them for every patient would be wrong for many, which is why the guideline leaves the choice among first-line and second-line options to the clinical situation and why this defense spends its effort on the situation rather than the ranking. The defense uses the guideline to settle whether quetiapine is a legitimate choice, and uses the patient's situation to settle whether it was the right choice now.
What Would Make Me Switch Earlier
Weight gain of more than 5% in the first six weeks, a rise in fasting glucose into the diabetic range, or sedation that threatens the patient's job. Any of these would prompt a cross-titration to lamotrigine, with the slower titration accepted because mood should by then be more stable.
How the Patient Took Part in the Choice
The patient was told about both options at the first visit. They chose the faster one, saying they could not face another six weeks feeling as they did, and that they would rather deal with weight later than lose their job now. The partner agreed. The patient's preference does not settle the clinical argument, but it weighs heavily in a choice between two reasonable first-line or second-line options, and it is recorded here because a defense that omits it describes a decision made for the patient rather than with them.
What Supervision Added
The supervising nurse practitioner agreed with the plan but asked two questions: whether lithium had been considered, given its evidence for reducing suicide risk in mood disorders, and whether the patient could manage blood levels. Lithium was discussed and set aside for now because the patient's alcohol use and the need for blood monitoring during a crisis made it less safe as a first step. It remains an option if the patient does not respond, and the patient was told so, so that a later suggestion of lithium would not come as a surprise.
What Remains Uncertain
Whether the partner's account of hypomania is accurate in every detail; the diagnosis rests on it. And whether this patient will accept a second medication change at 12 weeks, after a first change that is working. A patient who feels better may reasonably not want to switch, and the metabolic argument will need to be made again then, with the six-week results in hand.
References
Pacchiarotti, I., Bond, D. J., Baldessarini, R. J., Nolen, W. A., Grunze, H., Licht, R. W., Post, R. M., Berk, M., Goodwin, G. M., Sachs, G. S., Tondo, L., Findling, R. L., Youngstrom, E. A., Tohen, M., Undurraga, J., González-Pinto, A., Goldberg, J. F., Yildiz, A., Altshuler, L. L., . . . Vieta, E. (2013). The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. American Journal of Psychiatry, 170(11), 1249-1262. https://doi.org/10.1176/appi.ajp.2013.13020185
Sachs, G. S., Nierenberg, A. A., Calabrese, J. R., Marangell, L. B., Wisniewski, S. R., Gyulai, L., Friedman, E. S., Bowden, C. L., Fossey, M. D., Ostacher, M. J., Ketter, T. A., Patel, J., Hauser, P., Rapport, D., Martinez, J. M., Allen, M. H., Miklowitz, D. J., Otto, M. W., Dennehy, E. B., & Thase, M. E. (2007). Effectiveness of adjunctive antidepressant treatment for bipolar depression. New England Journal of Medicine, 356(17), 1711-1722. https://doi.org/10.1056/NEJMoa064135
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., Alda, M., MacQueen, G., Milev, R. V., Ravindran, A., O'Donovan, C., McIntosh, D., Lam, R. W., Vazquez, G., Kapczinski, F., . . . Berk, M. (2018). Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disorders, 20(2), 97-170. https://doi.org/10.1111/bdi.12609
NR 668 Week 4 instructions, in plain terms
State the plan first in a short paragraph so the reader knows exactly what is being defended. Then build the objection properly, in the words a skeptical colleague would use, not a weakened version that is easy to answer. Separate two things most writers merge: what the objection gets right, conceded openly and specifically, and what it does not settle, which is where your position holds. Use evidence to settle specific points rather than to fill space. Include the patient's preference and any supervisory input. Then give the plan as it stands after the challenge, showing what changed. Say what would make you change course and what remains uncertain.
Inside the NR 668 Week 4 example
The sample's plan is quetiapine to 300 mg with an escitalopram taper. The objection cites a body mass index of 31, an A1C of 5.8%, raised lipids, a parent with diabetes, sedation risk for a designer on deadlines and lamotrigine's strength for prevention. The defense concedes the metabolic risk and lamotrigine's long-term advantage, then holds on acute risk, lamotrigine's slow titration and quetiapine's first-line status. The patient chose the faster option, and supervision raised lithium. The revised plan brings glucose and lipids to six weeks, adds nutrition referral, caps the dose at the lowest effective level and plans a week-12 review of a move to lamotrigine. It also names what would prompt an earlier switch to lamotrigine.
NR 668 Week 4 rubric: what full points look like
Case defenses lose most when the objection is a straw version, raised only to be knocked down. Next is a defense that concedes nothing, which reads as stubborn rather than reasoned. Many writers merge what the objection gets right with what it fails to settle, so the position never becomes clear. Evidence is often piled up to fill space instead of placed where it settles a point. Defenses that leave out the patient's preference describe a decision made for the patient rather than with them. A plan that ends unchanged after the challenge suggests the objection was not taken seriously, which is what graders look for first. Defenses that never say what would trigger a change of course also make the plan look fixed.
NR 668 Week 4 help: mistakes that cost points
Writing a strong objection to your own plan feels uncomfortable, but it is what makes the defense worth reading. With a draft in hand, we can help you state the plan flatly, build the objection as a skeptical colleague would and separate what it gets right from what it does not settle. We can also help you show how the plan changed after the challenge. Asking a classmate to write the objection for you is often the fastest way to get a strong one. The plan and its defense are yours.
Get a NR 668 Week 4 example written to your instructions
Send the Week 4 instructions along with the case and the plan you are defending, and a custom example is written to that assignment and returned inside 24 to 48 hours. The first one is free. If your section names the objection, send that too, since the whole document is built around it.
More NR 668 papers and PMHNP samples
- NR 668 Week 1: Case Selection Post
- NR 668 Week 2: Case Conference Write-Up
- NR 668 Week 3: Evaluation Note
- NR 668 Week 5: Panel Review Write-up
- NR 668 Week 6: Safety Decision Write-up
- NR 668 Week 7: Practice Question Brief
- NR 668 Week 8: Capstone Case Paper
- NR 546 Week 4: Titration and Monitoring Plan
- NR 607 Week 4: Care Coordination Note
- NR 547 Week 4: Rule Out Analysis
- NR 606 Week 4: Plan Revision Note
NR 668 Week 4 questions, answered
Should I change my plan in response to the objection?
Only if the objection deserves it, and then say so plainly. Revising under a good argument is rewarded, because it shows the defense was a real examination rather than a performance. Revising under a weak one is not. The version that scores badly either way is the paper that quietly adjusts the plan without acknowledging that anything moved, which reads as evasion.
Where do I find an objection worth answering?
Usually inside the case. The alternative diagnosis you set aside, the medication a reasonable prescriber would have chosen instead, the family member who disagreed, the guideline that points a different way. Objections invented from outside the case tend to be generic, and generic objections produce generic answers. The strongest ones are the doubts you had yourself at the time.
How formal should the tone of a defense be?
Measured rather than combative. The document is addressed to a colleague who wants the patient to do well, not to an opponent, and writing that treats the objection as an attack tends to read as insecurity about the plan. Keeping the first person and the clinical register together works well here: I chose this, for these reasons, and here is what would have changed it.
Where can I find a free NR 668 Week 4 sample paper?
The complete case defense of quetiapine over lamotrigine for bipolar II depression appears in full here.
What changed in the NR 668 Week 4 plan after the objection?
Metabolic monitoring moved to six weeks, a nutrition referral was added, the dose was capped at the lowest effective level and a move to lamotrigine was planned.